Safety and Pharmacokinetics Study of CPL207280 Compound in Healthy Volunteers.
Status:
Completed
Trial end date:
2021-05-05
Target enrollment:
Participant gender:
Summary
The planned study is to determine the safety and pharmacokinetic properties of CPL207280
compound after single and multiple (two weeks) administration in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Celon Pharma SA
Collaborator:
National Center for Research and Development, Poland